Inovio Pharmaceuticals' (INO) Sell (E+) Rating Reaffirmed at Weiss Ratings

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report)'s stock had its "sell (e+)" rating reissued by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

INO has been the subject of a number of other research reports. Wall Street Zen downgraded Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Piper Sandler initiated coverage on Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They set an "overweight" rating and a $5.00 price target for the company. HC Wainwright reiterated a "neutral" rating and set a $3.00 price target on shares of Inovio Pharmaceuticals in a research note on Thursday, August 14th. Finally, Zacks Research downgraded Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Inovio Pharmaceuticals currently has an average rating of "Hold" and an average target price of $8.80.

Inovio Pharmaceuticals Price Performance

Inovio Pharmaceuticals stock opened at $2.56 on Wednesday. The stock's 50 day moving average is $2.17 and its 200 day moving average is $1.93. The firm has a market cap of $136.05 million, a P/E ratio of -0.98 and a beta of 1.65. Inovio Pharmaceuticals has a one year low of $1.30 and a one year high of $5.83.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02. Equities analysts anticipate that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Qube Research & Technologies Ltd purchased a new position in Inovio Pharmaceuticals in the second quarter valued at about $234,000. Nuveen LLC purchased a new position in Inovio Pharmaceuticals in the first quarter valued at about $168,000. Charles Schwab Investment Management Inc. boosted its stake in Inovio Pharmaceuticals by 38.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company's stock valued at $161,000 after acquiring an additional 27,429 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Inovio Pharmaceuticals by 22.4% in the first quarter. Bank of New York Mellon Corp now owns 75,422 shares of the biopharmaceutical company's stock valued at $123,000 after acquiring an additional 13,784 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in Inovio Pharmaceuticals in the first quarter valued at about $120,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.